Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17420132 | 0.80 | MEN1 (0.40) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL4109091 | 0.77 | HASPIN (0.37) | KMT2ANPC1RAB9AALDH1A1CCR1 | |
| SCHEMBL23985444 | 0.76 | MEN1 (0.43) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL28836041 | 0.76 | L3MBTL1 (0.55) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL12273053 | 0.74 | MEN1 (0.36) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL12273055 | 0.74 | MEN1 (0.36) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL2563638 | 0.73 | MAPK9 (0.41) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL29842006 | 0.73 | KMT2A (0.41) | KMT2AMEN1NPC1RAB9AALDH1A1 | |
| SCHEMBL1717209 | 0.72 | — | — | |
| SCHEMBL5045978 | 0.72 | GPR84 (0.50) | KMT2AMEN1NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 353 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109824602-B | Synthesis method of 4-chloro-2-methylthiopyrimidine | 南京哈柏医药科技有限公司 | 2023-10-27 | — | — | CN | claimed |
| CN-116283793-A | Synthesis process of 2-methylthio-4-chloro-5-bromopyrimidine | 南京哈柏医药科技有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-114539163-B | HIV-1 reverse transcriptase inhibitor and its synthesis process | 复旦大学 | 2023-05-30 | — | — | CN | claimed |
| CN-114539163-A | HIV-1 reverse transcriptase inhibitor and synthetic method thereof | 复旦大学 | 2022-05-27 | — | — | CN | claimed |
| CN-109824602-A | The synthetic method of the chloro- 2- methylthiopyrimidine of 4- | 南京哈柏医药科技有限公司 | 2019-05-31 | — | — | CN | claimed |
| EP-4143193-B1 | IMIDAZOPYRIMIDINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2026-04-22 | — | — | EP | disclosed |
| EP-3877382-B1 | NOVEL COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2026-03-18 | — | — | EP | disclosed |
| US-12559496-B2 | Imidazopyrimidines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-24 | — | — | US | disclosed |
| US-20260049086-A1 | CDK9 INHIBITORS | BAERENKRAFT THERAPEUTICS LLC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3619204-B1 | COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES | TIANLI BIOTECH PTY LTD (AU) | 2025-10-01 | — | — | EP | disclosed |
| CN-115867348-B | Imidazopyrimidines as IL-17 modulators | 詹森药业有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-113260616-B | Novel compounds for the treatment of respiratory diseases | 天莅生物技术有限公司 | 2025-05-02 | — | — | CN | disclosed |
| US-5593991-A | ANTIINFLAMMATORY, CYTOKINE INHIBITOR, CYCLOOXYGENASE INHIBITOR | SMITHKLINE BEECHAM CORPORATION | 1997-01-14 | — | — | US | disclosed |
| US-5593992-A | CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1996040143-A1 | IMIDAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0708768-A4 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORP (US) | 1996-08-21 | — | — | EP | disclosed |
| CN-1129447-A | Trisubstituted imidazoles having multiple therapeutic effects | SMITHKLINE BEECHAM CORP (US) | 1996-08-21 | — | — | CN | disclosed |
| WO-1996021452-A1 | CERTAIN 1,4,5-TRI-SUBSTITUTED IMIDAZOLE COMPOUNDS USEFUL AS CYTOKINE | SMITHKLINE BEECHAM CORPORATION (US) | 1996-07-18 | — | — | WO | disclosed |
| EP-0708768-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995002591-A1 | TRI-SUBSTITUTED IMIDAZOLES HAVING MULTIPLE THERAPEUTIC PROPERTIES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049086-A1 | CDK9 INHIBITORS | CDK9, CDK6, CDK19 | KMT2A 834/4885MEN1 3655/4885NPC1 2438/4885 |
| US-12559496-B2 | Imidazopyrimidines as modulators of IL-17 | IL17A, IL2, IL23R | KMT2A 3063/4885MEN1 2259/4885NPC1 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.